Janssen's canagliflozin clears Januvia and glimepiride at Phase III hurdle
This article was originally published in Scrip
Data from the first two head-to-head pivotal trials of Janssen/Mitsubishi Tanabe Pharma 's SGLT2 inhibitor show that it has improved efficacy over established antidiabetics, without any sign yet of the cancer and liver signals that have delayed the lead product in this class, AstraZeneca/ Bristol-Myers Squibb 's dapagliflozin, in the US.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.